Gosselies, Belgium, 24 November 2014 – BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the fields of bone diseases and orthopaedics, today announces the appointment of Dr Guy Heynen as Chief Clinical and Regulatory Officer. Dr Heynen will support Bone Therapeutics as it progresses its strong pipeline of regenerative bone disease and orthopaedic therapies through clinical development towards commercialisation.
Dr Heynen is a specialist in rheumatology and immunology, with extensive experience both in university medical practice and in the pharmaceutical industry. He has over 35 years’ experience in medical and regulatory affairs at local, regional and international levels and has a particular focus on management, team building and leadership. The majority of his career has been with Pfizer Inc., where he held a number of senior roles including Medical Director for Pfizer Switzerland, European Team Leader for the Alzheimer’s disease drug, Aricept, and Medical Team Leader for Pfizer’s anti-inflammatory drug franchise based in New York.
Dr Heynen also serves on the Boards of Euroscreen SA, Progenosis SA and as an advisor for Promethera Biosciences, roles which highlight his expertise and strong network in cell therapy. Dr Heynen remains a Regional Medical Monitor for Pfizer GmbH.
Dr Heynen started his career at the Belgian National Foundation for Research and in research roles at University Hospital, Liege, Belgium where he received his degree in medicine and rheumatology.
Enrico Bastianelli, CEO of Bone Therapeutics commented: “Guy Heynen has a distinguished track record both in hospital medical practice and industry. His understanding of clinical operations and regulatory affairs will be an invaluable asset to Bone Therapeutics as we move forward to advance our innovative late-stage pipeline of regenerative medicines in bone diseases and orthopaedics. His long-standing experience within major pharmaceutical companies around the world will be key in preparing to bring our products to market and supporting Bone Therapeutics’ development on a global scale. Dr Heynen’s experience advising cell therapy companies also provides important understanding of this growing sector.” Dr Guy Heynen, commented: “Bone Therapeutics is at the forefront of developing some of the most promising therapies for bone disease and orthopaedic medicine. I am privileged to be joining the Company at such an exciting time in its development and I look forward to working with the team to advance its innovative products towards commercialisation.”
About Bone Therapeutics
Bone Therapeutics is a leading biotechnology company specializing in the development of innovative regenerative therapies for the treatment of orthopaedic conditions. The current standard of care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative products containing regenerative osteoblastic/bone forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous cell product, is currently in pivotal Phase III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for treatment resistant osteoporosis. ALLOB®, its allogeneic cell product, is in Phase II for the treatment of delayed union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at www.bonetherapeutics.com For further information, please contact:
Bone Therapeutics SA
Tel.: +32 (0)2 529 59 90
Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
info@bonetherapeutics.com
Consilium Strategic Communications
Amber Bielecka, Mary-Jane
Elliott, Jessica Hodgson, Lindsey Neville
Tel.: +44 (0) 20 3 709 5700
bonetherapeutics@consiliumcomms.com
Help employers find you! Check out all the jobs and post your resume.
Dr Heynen is a specialist in rheumatology and immunology, with extensive experience both in university medical practice and in the pharmaceutical industry. He has over 35 years’ experience in medical and regulatory affairs at local, regional and international levels and has a particular focus on management, team building and leadership. The majority of his career has been with Pfizer Inc., where he held a number of senior roles including Medical Director for Pfizer Switzerland, European Team Leader for the Alzheimer’s disease drug, Aricept, and Medical Team Leader for Pfizer’s anti-inflammatory drug franchise based in New York.
Dr Heynen also serves on the Boards of Euroscreen SA, Progenosis SA and as an advisor for Promethera Biosciences, roles which highlight his expertise and strong network in cell therapy. Dr Heynen remains a Regional Medical Monitor for Pfizer GmbH.
Dr Heynen started his career at the Belgian National Foundation for Research and in research roles at University Hospital, Liege, Belgium where he received his degree in medicine and rheumatology.
Enrico Bastianelli, CEO of Bone Therapeutics commented: “Guy Heynen has a distinguished track record both in hospital medical practice and industry. His understanding of clinical operations and regulatory affairs will be an invaluable asset to Bone Therapeutics as we move forward to advance our innovative late-stage pipeline of regenerative medicines in bone diseases and orthopaedics. His long-standing experience within major pharmaceutical companies around the world will be key in preparing to bring our products to market and supporting Bone Therapeutics’ development on a global scale. Dr Heynen’s experience advising cell therapy companies also provides important understanding of this growing sector.” Dr Guy Heynen, commented: “Bone Therapeutics is at the forefront of developing some of the most promising therapies for bone disease and orthopaedic medicine. I am privileged to be joining the Company at such an exciting time in its development and I look forward to working with the team to advance its innovative products towards commercialisation.”
About Bone Therapeutics
Bone Therapeutics is a leading biotechnology company specializing in the development of innovative regenerative therapies for the treatment of orthopaedic conditions. The current standard of care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative products containing regenerative osteoblastic/bone forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous cell product, is currently in pivotal Phase III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for treatment resistant osteoporosis. ALLOB®, its allogeneic cell product, is in Phase II for the treatment of delayed union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at www.bonetherapeutics.com For further information, please contact:
Bone Therapeutics SA
Tel.: +32 (0)2 529 59 90
Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
info@bonetherapeutics.com
Consilium Strategic Communications
Amber Bielecka, Mary-Jane
Elliott, Jessica Hodgson, Lindsey Neville
Tel.: +44 (0) 20 3 709 5700
bonetherapeutics@consiliumcomms.com
Help employers find you! Check out all the jobs and post your resume.
